SCHEMBL2877347

SCHEMBL2877347

CC(C)C(C)NC(=O)c1cc(F)nc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.46
TAS1R1 Q7RTX1 2/20 0.46
TAS1R2 Q8TE23 2/20 0.46
CYP2C9 P11712 2/20 0.41
MAPK14 Q16539 2/20 0.41
NAMPT P43490 5/20 0.40
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
TRPV1 Q8NER1 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MLYCD O95822 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866110 1.00 TAS1R3 (0.46) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL23309675 0.85 MLYCD (0.47) ALDH1A1HPGDMLYCDNPSR1
SCHEMBL2856859 0.83 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL2909101 0.82 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL24571660 0.81 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL2859570 0.80 PREP (0.50) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL24571254 0.80 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL13304124 0.75 TRPV1 (0.45) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL13304424 0.75 TRPV1 (0.45) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14
SCHEMBL3129576 0.75 MAPK1 (0.47) TAS1R3TAS1R1TAS1R2CYP2C9MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137376-A1 AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
US-20100137376-A1 AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
US-20100137376-A1 AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
EP-2174931-A1 AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137376-A1 AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME NAAA, NAT1, SAT1 TAS1R3 4053/4885TAS1R1 3002/4885TAS1R2 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.